{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T03:01:32Z","timestamp":1771210892028,"version":"3.50.1"},"reference-count":25,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Ocrelizumab is a humanized monoclonal antibody, which acts as an anti\u2010CD20 antibody. It is used as a treatment of both relapsing\u2013remitting multiple sclerosis (RRMS) and Progressive types. The aim of this study is to report the first patient with alopecia universalis after switching from rituximab to ocrelizumab. A 37\u2010year\u2010old woman with a history of SPMS, diagnosed 8\u2009years ago, used to be treated with rituximab. Her drug was switched to ocrelizumab from 6\u2009months ago. She presented with patchy scalp hair loss a day after receiving the second dose of ocrelizumab. Her hair loss rapidly progressed in 3\u20134\u2009days to total body hair loss in a patchy pattern. Ocrelizumab may be responsible for autoimmune reactions such as alopecia universalis in immunocompromised patients.<\/jats:p>","DOI":"10.1111\/1756-185x.70028","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T23:24:02Z","timestamp":1734996242000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Alopecia Universalis in a Multiple Sclerosis Patient After Switching From Rituximab to Ocrelizumab: A Case Report"],"prefix":"10.1111","volume":"27","author":[{"given":"Mahshid","family":"Mahyad","sequence":"first","affiliation":[{"name":"Department of Neurology, Faculty of Medicine Mashhad University of Medical Sciences  Mashhad Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahdieh","family":"Baghaei","sequence":"additional","affiliation":[{"name":"Department of Radiology, Faculty of Medicine Mashhad University of Medical Sciences  Mashhad Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ava","family":"Baghaei","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine Mashhad University of Medical Sciences  Mashhad Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8373-6053","authenticated-orcid":false,"given":"Mohammadali","family":"Nahayati","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine Mashhad University of Medical Sciences  Mashhad Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"issue":"12","key":"e_1_2_1_7_2_1","first-page":"423","article-title":"Ocrelizumab: Its Efficacy and Safety in Multiple Sclerosis","volume":"66","author":"Juanatey A.","year":"2018","journal-title":"Revista de Neurologia"},{"key":"e_1_2_1_7_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756285615601933"},{"key":"e_1_2_1_7_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1446944"},{"key":"e_1_2_1_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606468"},{"key":"e_1_2_1_7_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X20919614"},{"key":"e_1_2_1_7_7_1","doi-asserted-by":"publisher","DOI":"10.24018\/ejmed.2023.5.3.1697"},{"key":"e_1_2_1_7_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11133702"},{"key":"e_1_2_1_7_9_1","doi-asserted-by":"publisher","DOI":"10.2478\/enr-2021-0018"},{"key":"e_1_2_1_7_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/11795735211037785"},{"issue":"8","key":"e_1_2_1_7_11_1","first-page":"ofy174","article-title":"Infectious Complications of Multiple Sclerosis Therapies: Implications for Screening, Prophylaxis, and Management. Open Forum","volume":"5","author":"Epstein D. J.","year":"2018","journal-title":"Infectious Diseases"},{"key":"e_1_2_1_7_12_1","doi-asserted-by":"crossref","DOI":"10.1177\/11795735221109674","article-title":"Alopecia in Multiple Sclerosis Patients Treated With Disease Modifying Therapies","volume":"14","author":"Porwal M. H.","year":"2022","journal-title":"Journal of Central Nervous System Disease"},{"issue":"7522","key":"e_1_2_1_7_13_1","first-page":"951","article-title":"Psychological Impact of Alopecia","volume":"331","author":"Hunt N.","year":"2005","journal-title":"Psychological Impact of Alopecia Bmj"},{"key":"e_1_2_1_7_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad113.167"},{"key":"e_1_2_1_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.04.1141"},{"key":"e_1_2_1_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.12209"},{"key":"e_1_2_1_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2003.tb00458.x"},{"issue":"1","key":"e_1_2_1_7_18_1","article-title":"Tolerability and Safety of Switching From Rituximab to Ocrelizumab: Evaluating Factors Associated With Infusion Related Reactions","volume":"8","author":"Alvarez E.","year":"2022","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"e_1_2_1_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.12.005"},{"key":"e_1_2_1_7_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706383"},{"key":"e_1_2_1_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61649-8"},{"key":"e_1_2_1_7_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.1625"},{"key":"e_1_2_1_7_23_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162752"},{"key":"e_1_2_1_7_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458518757930"},{"key":"e_1_2_1_7_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.2.435.435"},{"key":"e_1_2_1_7_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23732"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.70028","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1756-185X.70028","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.70028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T02:05:21Z","timestamp":1771207521000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.70028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1111\/1756-185X.70028"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.70028","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"2024-08-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70028"}}